Date added: 16/12/2015 Top Story: Novel Therapeutic Direction for Common Metabolic Disorders

 

 

Given that this year's buzz-words have been "innovation" and "game-changing," our last e-newsletter for the year is full of things that are different and unusual.

 

Cell-based Research

 

Novel Therapeutic Direction for Common Metabolic Disorders

 

Researchers have identified individual bacterial strains that directly modulated the activation of intestinal farnesoid X receptor (FXR). Their article, titled "Bacterial metabolites directly modulate farnesoid X receptor activity," was published in the journal, Nutrition & Metabolism, on 24 November 2015. Here, the authors conclude that two bacteria, B. dorei and E. limosum, "have potential value as useful tools for the study of complex FXR functions, and provide a novel therapeutic direction for the treatment or prevention of common metabolic disorders." Three cell lines were used in the study (SW480, HepG2 and CACO-2) and were purchased from ECACC.

 

To read the article, click here.

 

First-time Multi-omic Profiling of Neuroblastoma Cell Lines

 

For the first time, researchers have presented the integrative profiling of thirteen MYCN-amplified neuroblastoma cell lines at the genomic, transcriptomic and translatomic levels. Their article, titled "Translational compensation of genomic instability in neuroblastoma," was published in the journal, Scientific Reports, on 24 September 2015. Six of the thirteen cell lines (CHP-134, IMR-32, KELLY, LAN-1, SK-N-BE2 and SK-N-DZ) were purchased from ECACC.

 

To read the article, click here.

 

Innovation Awards: Alzheimer's in a Dish

 

To read the article, click here.

 

How CellBank Australia Can Help

 

CellBank Australia is Australia's sole national not-for-profit cell line repository.

 

Novel Mammalian Cell Lines: Catalog Deposit Service

 

CellBank Australia accepts novel cell lines as catalog deposits and has an agreement with the European Collection of Authenticated Cell Cultures (ECACC; Salisbury, UK) for the distribution of our cell line catalog to researchers outside of Australia and New Zealand. 

 

Have you established some novel mammalian cell lines? Are you continually having to ship out your novel lines to collaborators? Might you be missing out on additional research opportunities because collaborators can't afford to pay international shipping fees for your novel cell lines? If you have answered yes to any of those questions, do yourself a favor and get in touch with CellBank Australia.

 

We can make it cheaper and easier for researchers around the world to access quality-controlled stock of your novel cell lines. We offer a free-of-charge catalog deposit service and have an agreement with ECACC for the distribution and marketing of our unique cell lines outside of Australasia.

 

To learn more about our catalog deposit service, click here.

 
Loading...